Glucocorticoid receptor overexpression in forebrain: A mouse model of increased emotional lability

Proceedings of the National Academy of Sciences of the United States of America

Volumn 101, Issue 32, 2004, Pages 11851-11856

  Wei, Qiang ^a   Lu, Xin Yun ^a,e   Liu, Li ^a   Schafer, Gwen ^a   Shieh, Kun Ruey ^a   Burke, Sharon ^a   Robinson, Terry E ^b   Watson, Stanley J ^a,c   Seasholtz, Audrey F ^a,d   Akil, Huda ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID RECEPTOR; SEROTONIN 1A RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; BRAIN REGION; CONTROLLED STUDY; DEPRESSION; EMOTION; FOREBRAIN; GENE EXPRESSION; GENE OVEREXPRESSION; MENTAL INSTABILITY; MOOD DISORDER; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; WILD TYPE;

AFFECTIVE SYMPTOMS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; COCAINE; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; GENE EXPRESSION REGULATION; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; MOOD DISORDERS; PROSENCEPHALON; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, GLUCOCORTICOID;

ANIMALIA; MUS MUSCULUS;

EID: 4143091546     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0402208101     Document Type: Article

References (36)

1. Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Keller, M., Warshaw, M., Clayton, P. & Goodwin, F. (1995) Arch. Gen. Psychiatry 52, 114-123.
2. El-Mallakh, R. S. & Karippot, A. (2002) Psychiatr. Serv. 53, 580-584.
3. Sapolsky, R. M., Krey, L. C. & McEwen, B. S. (1984) Proc. Natl. Acad. Sci. USA 81, 6174-6177.
4. Akil, H. & Morano, M. (1995) in the Fourth Generation of Progress, eds. Bloom, F. & Kupfer, D. (Raven, New York), pp. 773-785.
5. McEwen, B. S. & Sapolsky, R. M. (1995) Curr. Opin. Neurobiol. 5, 205-216.
6. Meaney, M. J., Diorio, J., Francis, D., Widdowson, J., LaPlante, P., Caldji, C., Sharma, S., Seckl, J. R. & Plotsky, P. M. (1996) Dev. Neurosci. 18, 49-72.
7. De Kloet, E. R., Vreugdenhil, E., Oitzl, M. S. & Joels, M. (1998) Endocr. Rev. 19, 269-301.
8. Roozendaal, B., Griffith, Q. K., Buranday, J., De Quervain D. J. & McGaugh, J. L. (2003) Proc. Natl. Acad. Sci. USA 100, 1328-1333.
9. Holsboer, F. (2000) Neuropsychopharmacology 23, 477-501.
10. Korte, S. M. (2001) Neurosci. Biobehav. Rev. 25, 117-142.
11. Kabbaj, M., Devine, D. P., Savage, V. R. & Akil, H. (2000) J. Neurosci. 20, 6983-6988.
12. Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) Cell 93, 531-541.
13. Tronche, F., Kellendonk, C., Kretz, O., Gass, P., Anlag, K., Orban, P. C., Bock, R., Klein, R. & Schutz, G. (1999) Nat. Genet. 23, 99-103.
14. Pepin, M. C., Pothier, F. & Barden, N. (1992) Nature 355, 725-728.
15. Barden, N., Stec, I. S., Montkowski, A., Holsboer, F. & Reul, J. M. (1997) Neuroendocrinology 66, 212-220.
16. Rochford, J., Beaulieu, S., Rousse, I., Glowa, J. R. & Barden, N. (1997) Psychopharmacology 132, 145-152.
17. Dijkstra, I., Tilders, F. J., Aguilera, G., Kiss, A., Rabadan-Diehl, C., Barden, N., Karanth, S., Holsboer, F. & Reul, J. M. (1998) J. Neurosci. 18, 3909-3918.
18. Danielsen, M., Northrop, J. P. & Ringold, G. M. (1986) EMBO J. 5, 2513-2522.
19. Mayford, M., Bach, M. E., Huang, Y. Y., Wang, L., Hawkins, R. D. & Kandel, E. R. (1996) Science 274, 1678-1683.
20. Schramm, N. L., McDonald, M. P. & Limbird, L. E. (2001) J. Neurosci. 21, 4875-4882.
21. Lucki, I. (1997) Behav. Pharmacol. 8, 523-532.
22. West, A. P. (1990) Prog. Neuropsychopharmacol. Biol. Psychiatry 14, 863-877.
23. Piazza, P. V. & Le Moal, M. (1998) Trends Pharmacol. Sci. 19, 67-74.
24. Kalivas, P. W. & Stewart, J. (1991) Brain Res. Brain Res. Rev. 16, 223-244.
25. Robinson, T. E. & Berridge, K. C. (2003) Annu. Rev. Psychol. 54, 25-53.
26. Koob, G. F. & Heinrichs, S. C. (1999) Brain Res. 848, 141-152.
27. Torres, G. E., Gainetdinov, R. R. & Caron, M. G. (2003) Nat. Rev. Neurosci. 4, 13-25.
28. Leonard, B. E. (1997) J. Psychopharmacol. 11, Suppl. 4, 39-47.
29. Pierce, R. C. & Kalivas, P. W. (1997) Brain Res. Brain Res. Rev. 25, 192-216.
30. Koob, G. F., Sanna, P. P. & Bloom, F. E. (1998) Neuron 21, 467-476.
31. Meijer, O. C. & De Kloet, E. R. (1995) J. Neuroendocrinol. 7, 653-657.
32. Lopez, J. F., Chalmers, D. T., Little, K. Y. & Watson, S. J. (1998) Biol. Psychiatry 43, 547-573.
33. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) Science 301, 805-809.
34. Blier, P. & de Montigny, C. (1994) Trends Pharmacol. Sci. 15, 220-226.
35. Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E. E., Schold, C. & Schatzberg, A. F. (2002) Biol. Psychiatry 52, 386-392.
36. Young, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M. & Ferrier, I. N. (May 5, 2004) Neuropsychopharmacology, doi:10.1038/sj.npp. 1300471.